Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06916338
Overview
This study aims to evaluate the diagnostic accuracy (sensitivity, specificity, positive/negative predictive value, and overall accuracy) of 18F-FAPI-04 PET imaging in breast cancer for detecting fibroblast activation protein (FAP)-rich lesions. Additionally, the study will longitudinally monitor dynamic changes in FAP expression levels and tumor size during therapy, including chemotherapy, targeted therapy, or immunotherapy.The non-invasive nature of 18F-FAPI-04 PET addresses limitations of traditional biopsy-dependent stromal evaluation, offering whole-body quantification of tumor microenvironment dynamics to optimize therapeutic decision-making.
Sponsor
The Affiliated Hospital of Qingdao University
Phase
N/A
Contacts
Zhenguang Wang
wangzhenguang@qde.edu.cn
+86-0532-82913318
ClinicalTrials.gov
NCT06916338Drug / Compound
Help us improve your experience